vs

Side-by-side financial comparison of OPTICAL CABLE CORP (OCC) and Avidity Biosciences, Inc. (RNA). Click either name above to swap in a different company.

OPTICAL CABLE CORP is the larger business by last-quarter revenue ($19.8M vs $12.5M, roughly 1.6× Avidity Biosciences, Inc.). OPTICAL CABLE CORP runs the higher net margin — 0.2% vs -1398.3%, a 1398.6% gap on every dollar of revenue. On growth, Avidity Biosciences, Inc. posted the faster year-over-year revenue change (434.0% vs 1.8%). OPTICAL CABLE CORP produced more free cash flow last quarter ($718.8K vs $-156.9M). Over the past eight quarters, Avidity Biosciences, Inc.'s revenue compounded faster (138.5% CAGR vs 15.5%).

Optical Cable Corporation, headquartered in Roanoke, Virginia, manufactures fiber optical cable. The company's cable is largely used for telecommunications and is sold both in the US and seventy other countries worldwide. OCC also manufactures military land tactical fiber optic cable for the U.S. military.

Eli Lilly and Company, doing business as Lilly, is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by Eli Lilly, a pharmaceutical chemist and Union army veteran during the American Civil War for whom the company was later named.

OCC vs RNA — Head-to-Head

Bigger by revenue
OCC
OCC
1.6× larger
OCC
$19.8M
$12.5M
RNA
Growing faster (revenue YoY)
RNA
RNA
+432.3% gap
RNA
434.0%
1.8%
OCC
Higher net margin
OCC
OCC
1398.6% more per $
OCC
0.2%
-1398.3%
RNA
More free cash flow
OCC
OCC
$157.6M more FCF
OCC
$718.8K
$-156.9M
RNA
Faster 2-yr revenue CAGR
RNA
RNA
Annualised
RNA
138.5%
15.5%
OCC

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
OCC
OCC
RNA
RNA
Revenue
$19.8M
$12.5M
Net Profit
$48.6K
$-174.4M
Gross Margin
31.9%
Operating Margin
1.4%
-1513.5%
Net Margin
0.2%
-1398.3%
Revenue YoY
1.8%
434.0%
Net Profit YoY
-87.0%
-117.0%
EPS (diluted)
$-1.27

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
OCC
OCC
RNA
RNA
Q4 25
$19.8M
Q3 25
$19.9M
$12.5M
Q2 25
$17.5M
$3.8M
Q1 25
$15.7M
$1.6M
Q4 24
$19.5M
$3.0M
Q3 24
$16.2M
$2.3M
Q2 24
$16.1M
$2.0M
Q1 24
$14.9M
$3.5M
Net Profit
OCC
OCC
RNA
RNA
Q4 25
$48.6K
Q3 25
$301.9K
$-174.4M
Q2 25
$-697.9K
$-157.3M
Q1 25
$-1.1M
$-115.8M
Q4 24
$373.5K
$-102.3M
Q3 24
$-1.6M
$-80.4M
Q2 24
$-1.6M
$-70.8M
Q1 24
$-1.4M
$-68.9M
Gross Margin
OCC
OCC
RNA
RNA
Q4 25
31.9%
Q3 25
31.7%
Q2 25
30.4%
Q1 25
29.4%
Q4 24
33.5%
Q3 24
24.2%
Q2 24
25.1%
Q1 24
25.0%
Operating Margin
OCC
OCC
RNA
RNA
Q4 25
1.4%
Q3 25
2.8%
-1513.5%
Q2 25
-2.4%
-4448.7%
Q1 25
-5.4%
-8360.9%
Q4 24
3.4%
-4069.6%
Q3 24
-8.2%
-4200.9%
Q2 24
-8.1%
-4040.4%
Q1 24
-9.4%
-2178.6%
Net Margin
OCC
OCC
RNA
RNA
Q4 25
0.2%
Q3 25
1.5%
-1398.3%
Q2 25
-4.0%
-4089.3%
Q1 25
-7.0%
-7360.0%
Q4 24
1.9%
-3439.5%
Q3 24
-9.6%
-3441.7%
Q2 24
-9.9%
-3461.8%
Q1 24
-9.6%
-1943.4%
EPS (diluted)
OCC
OCC
RNA
RNA
Q4 25
Q3 25
$-1.27
Q2 25
$-1.21
Q1 25
$-0.90
Q4 24
$-0.80
Q3 24
$-0.65
Q2 24
$-0.65
Q1 24
$-0.18
$-0.79

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
OCC
OCC
RNA
RNA
Cash + ST InvestmentsLiquidity on hand
$237.5K
$350.2M
Total DebtLower is stronger
Stockholders' EquityBook value
$16.5M
$1.9B
Total Assets
$40.1M
$2.1B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
OCC
OCC
RNA
RNA
Q4 25
$237.5K
Q3 25
$421.4K
$350.2M
Q2 25
$894.3K
$243.9M
Q1 25
$128.3K
$254.2M
Q4 24
$244.2K
$219.9M
Q3 24
$796.7K
$370.2M
Q2 24
$1.1M
$575.8M
Q1 24
$221.0K
$471.4M
Stockholders' Equity
OCC
OCC
RNA
RNA
Q4 25
$16.5M
Q3 25
$18.2M
$1.9B
Q2 25
$19.1M
$1.2B
Q1 25
$19.7M
$1.3B
Q4 24
$20.8M
$1.4B
Q3 24
$20.4M
$1.5B
Q2 24
$21.8M
$1.2B
Q1 24
$23.3M
$830.9M
Total Assets
OCC
OCC
RNA
RNA
Q4 25
$40.1M
Q3 25
$40.2M
$2.1B
Q2 25
$39.1M
$1.4B
Q1 25
$37.8M
$1.5B
Q4 24
$40.4M
$1.6B
Q3 24
$37.6M
$1.6B
Q2 24
$39.9M
$1.3B
Q1 24
$40.5M
$951.5M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
OCC
OCC
RNA
RNA
Operating Cash FlowLast quarter
$797.3K
$-156.2M
Free Cash FlowOCF − Capex
$718.8K
$-156.9M
FCF MarginFCF / Revenue
3.6%
-1257.6%
Capex IntensityCapex / Revenue
0.4%
5.7%
Cash ConversionOCF / Net Profit
16.40×
TTM Free Cash FlowTrailing 4 quarters
$1.1M
$-592.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
OCC
OCC
RNA
RNA
Q4 25
$797.3K
Q3 25
$-2.2M
$-156.2M
Q2 25
$141.4K
$-199.7M
Q1 25
$2.7M
$-124.8M
Q4 24
$-1.5M
$-99.9M
Q3 24
$552.4K
$-65.6M
Q2 24
$373.7K
$-65.0M
Q1 24
$-261.1K
$-70.4M
Free Cash Flow
OCC
OCC
RNA
RNA
Q4 25
$718.8K
Q3 25
$-2.3M
$-156.9M
Q2 25
$73.4K
$-203.0M
Q1 25
$2.6M
$-128.6M
Q4 24
$-1.6M
$-103.8M
Q3 24
$475.2K
$-67.3M
Q2 24
$218.2K
$-65.5M
Q1 24
$-341.5K
$-71.3M
FCF Margin
OCC
OCC
RNA
RNA
Q4 25
3.6%
Q3 25
-11.4%
-1257.6%
Q2 25
0.4%
-5277.1%
Q1 25
16.5%
-8174.3%
Q4 24
-8.1%
-3491.0%
Q3 24
2.9%
-2881.8%
Q2 24
1.4%
-3204.6%
Q1 24
-2.3%
-2012.3%
Capex Intensity
OCC
OCC
RNA
RNA
Q4 25
0.4%
Q3 25
0.4%
5.7%
Q2 25
0.4%
86.9%
Q1 25
0.5%
238.6%
Q4 24
0.3%
131.7%
Q3 24
0.5%
72.9%
Q2 24
1.0%
26.0%
Q1 24
0.5%
25.8%
Cash Conversion
OCC
OCC
RNA
RNA
Q4 25
16.40×
Q3 25
-7.29×
Q2 25
Q1 25
Q4 24
-4.08×
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons